As artificial intelligence systems become increasingly sophisticated, questions once confined to philosophy are rapidly entering mainstream scientific and public debate: Can AI possess consciousness? Could animals, organoids, or even fetuses have subjective experiences?

A research team led by Director Hakwan LAU of the Center for Neuroscience Imaging Research within the Institute for Basic Science (IBS), together with collaborators from the Université de Montréal and New York University, has published a new analysis arguing that current scientific methods may not yet be capable of reliably answering such questions. The paper critically examines how consciousness is currently studied in neuroscience and argues that many widely used experimental approaches fail to clearly distinguish subjective experience from general information processing.

Artificial intelligence models using electronic health records and patient-reported outcomes may help identify cancer survivors at increased risk for emergency department visits, hospitalizations and worsening symptoms after treatment. Findings suggest AI-driven risk forecasting could help care teams intervene earlier with more proactive survivorship support.

A recent comprehensive review highlights that artificial intelligence, by integrating multiscale data from wearables, multiomics, imaging and largescale cohorts, can finally turn the “exercise is medicine” slogan into truly individualized clinical practice. This openaccess article entitled “Artificial intelligenceempowered multiscale data integration for precision exercise biomedicine” (DOI: 10.1515/teb20260009), was published in Translational Exercise Biomedicine (ISSN: 2942-6812), an official partner journal of International Federation of Sports Medicine (FIMS).

What if the body had a shuttle service to deliver medication directly to the brain? One research team believes they might have a way to make it a reality.

Peter Davies, MD, PhD, deputy director at the Texas A&M Health Institute of Biosciences and Technology, and his colleagues have been awarded a Dementia and Alzheimer’s Initiative (DARI) seedling grant from Texas A&M Health for their proposal to deliver medication past the blood-brain barrier, a persistent obstacle in neuroscience.